Similarly, Yan et al. also found that IRF-1 can upregulate PD-L1 and result in tumor cell evasion of antitumor immunity via T cell interactions in human hepatocellular carcinoma [77]. This evidence concerns the gene IRF1 and hepatocellular carcinoma.